Pharmaceuticals News and Research

RSS

G20 summit opens in Seoul; development plan announcement expected

The world's biggest rich and emerging powers escalated a war of words over trade and currencies Thursday, as leaders opened a G20 summit [in Seoul, South Korea] struggling to iron out distortions that threaten global growth, Agence France-Presse reports in an article examining some of the major disputes.

11 Nov 2010

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

Aradigm Corporation today announced financial results for the third quarter and nine months ended September 30, 2010.

11 Nov 2010

EvaluatePharma joins Boston biotech community

EvaluatePharma USA, Inc. the online analysis service for the global biotechnology and pharmaceutical sector, was welcomed into Boston's biotech community today by Mayor Menino at the opening of their new office in Boston, the #1 life sciences cluster in the US.

11 Nov 2010

Cadence prices underwritten public offering

Cadence Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share. The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $86.2 million.

11 Nov 2010

Terahertz waves can manipulate network of molecules

As if borrowing from a scene in a science fiction movie, researchers at Kyoto University have successfully developed a kind of tractor beam that can be used to manipulate the network of the molecules. In a paper soon to be published in Physical Review Letters, the team has demonstrated a technique using terahertz pulses that could have broad applications in the chemical and pharmaceutical industries.

11 Nov 2010

40% of older Americans skip doses or do not take medications

Advances in the pharmaceutical industry over the past several decades, have lead to thousands of new medications that allow physicians to treat and prevent disease. Many conditions that not so long ago were fatal are now managed effectively and safely.

11 Nov 2010

World's largest data base on protein motions

After four years of conducting intensive calculations in the supercomputer MareNostrum at the Barcelona Supercomputing Center, scientists headed by Modesto Orozco at the Institute for Research in Biomedicine (IRB Barcelona) have presented the world's largest data base on protein motions. Called MoDEL, this new database holds more than 1,700 proteins and is partially accessible through Internet to researchers worldwide. MoDEL has been developed to study the basic biology of proteins and to accelerate and facilitate the design of new pharmaceutical agents.

11 Nov 2010

TFAH's new report on flu finds higher hospitalization rates among African Americans

H1N1 flu hospitalization rates for African-Americans, Hispanics, and American Indian/Alaska Natives were nearly two to one higher than rates for Whites during the 2009-2010 flu season, according to a new report, Fighting Flu Fatigue, from the Trust for America's Health (TFAH). At the same time, both H1N1 and seasonal flu vaccination rates were lower for African Americans and Hispanics than for Whites.

11 Nov 2010

Neurons recycle protein components for neurotransmitter release

Neurons communicate via chemical transmitters which they store in the bubble-like synaptic vesicles and release as required. To be able to react reliably to stimulation, neurons must have a certain number of "acutely releasable" vesicles. With the help of a new method, neuroscientists at the Max Planck Institute of Experimental Medicine in G-ttingen have now discovered that neurons systematically recycle the protein components necessary for transmitter release and in this way guarantee the reliability of signal transmission in the brain.

11 Nov 2010

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ.

11 Nov 2010

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

In a major breakthrough that comes after decades of research and nearly half a billion treatments in humans, scientists have finally unlocked how a key anti-parasitic drug kills the worms brought on by the filarial diseases river blindness and elephantitis.

11 Nov 2010

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

11 Nov 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today publication of data demonstrating that its sapacitabine oral nucleoside analog works synergistically with histone deacetylase (HDAC) inhibitors to induce significant reductions in tumor cell growth in both in vitro and in vivo preclinical models.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

New research has found that a mother's poor nutrition during pregnancy and nursing can cause problems for her offspring's ability to process medications, even well into adulthood.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE).

11 Nov 2010

Adolor receives U.S. Patent for beloxepin to treat pain

Adolor Corporation today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.

11 Nov 2010

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

11 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010

Pharmaceuticals News and Research

G20 summit opens in Seoul; development plan announcement expected

Aradigm reports $1.3M net income for third quarter 2010 vs. $3.0M net loss for third quarter 2009

EvaluatePharma joins Boston biotech community

Cadence prices underwritten public offering

Terahertz waves can manipulate network of molecules

40% of older Americans skip doses or do not take medications

World's largest data base on protein motions

TFAH's new report on flu finds higher hospitalization rates among African Americans

Neurons recycle protein components for neurotransmitter release

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

Evotec revenues increase 33% to € 38.8 m during first nine months of 2010

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Mother's poor nutrition during pregnancy affects offspring's ability to process medications

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Adolor receives U.S. Patent for beloxepin to treat pain

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence